Jushi Holdings Inc. (“Jushi” or the
“Company”) (CSE: JUSH)
(OTCMKTS:
JUSHF), vertically integrated, multi-state cannabis
operator, announced its financial results for the third quarter
ended September 30, 2020. All financial information is
provided in U.S. dollars unless otherwise indicated.
Third Quarter
2020 Financial
Highlights
- Total revenue increased 67 percent
sequentially to $24.9 million
- Gross profit of $12.3 million, an
increase of 64 percent sequentially
- Net loss of $30 million
- Adjusted EBITDA1 of $1.9 million, a
$3.1 million improvement as compared to the second quarter of
2020
- $43.2 million of cash and
marketable securities on the balance sheet as of September 30, 2020
and approximately $73 million on pro forma basis for same period
including the October equity raise
Third Quarter
Operational Highlights
- Closed equity acquisition of
Pennsylvania grower-processor permit holder
- Closed on an approximate $33
million debt financing of 10 percent senior secured notes and
warrants
- Opened 10th BEYOND/HELLOTM retail
location and the 8th Pennsylvania Medical Marijuana dispensary in
Reading, Pennsylvania
Recent Developments
- On November 24,
2020, the Company has exercised its right to accelerate the expiry
date of subordinate voting share purchase warrants issued to
participants in the Company's previously-announced private
placement offerings, which closed in April 2018 and June 2018. The
Company expects redemptions of these warrants to result in cash
proceeds of approximately USD$30 million and in the issuance of
approximately 15 million additional subordinate voting
shares. However, there can be no assurance that any of the
warrants will be exercised prior to the accelerated expiry
date
-
On November 23, 2020, Jushi announced its plans to nearly double
the square footage of its Pennsylvania grower-processor facility in
Scranton, PA to more than 160,000 square feet in a phased
expansion, which will nearly triple its canopy space to
approximately 98,000 square feet
-
The first phase of the expansion is expected to come online in
mid-2021 and the final phase will be complete in Q2 2022
-
On November 20, 2020, the Company announced it increased its
majority ownership stake in its Virginia-based pharmaceutical
processor license holder Dalitso LLC from ~62% to 79%, and plans to
begin retail sales on December 1, 2020
-
On November 19, 2020, the Company announced that Dalitso LLC,
the Company’s majority-owned, Virginia based pharmaceutical
processor permit holder, has commenced operations at its
cultivation, manufacturing, processing and retail facility in
Manassas, Virginia and that the Company’s retail brand,
BEYOND/HELLOTM, will begin dispensing medical marijuana dispensary
sales on December 1, 2020
-
On November 9, 2020, the Company announced the award of a
provisional license for a medical cannabis cultivation in Portugal
to its majority owned subsidiary Jushi Europe. Jushi is
contemplating a spin-off to shareholders of Jushi Holdings Inc.’s
51% ownership in Jushi Europe
-
On October 23, 2020, the Company closed on an approximate $29
million in net proceeds for its overnight marketed equity financing
with proceeds to be used for opportunistic acquisitions. As of
October 31, 2020, the Company had approximately $73 million in cash
and short-term investments
-
On October 14, 2020, the Company opened 11th BEYOND/HELLOTM retail
location in Santa Barbara, California
1 See “Reconciliation of Non-IFRS Financial
Measures” at the end of this press release for more information
regarding the Company’s use of non-IFRS financial measures.
Management Commentary
“Jushi delivered another outstanding quarter,
generating revenues at the high-end of our previously provided
guidance range and achieving Adjusted EBITDA profitability for the
first time in the Company’s history,” said Jim Cacioppo, Chief
Executive Officer, Chairman and Founder of Jushi. “Our strategic
roll out continues and I’m pleased with the initial reception
following the recent openings of our latest BEYOND/HELLOTM retail
stores in Santa Barbara, California and Reading, Pennsylvania. As
previously announced, we are also looking forward to opening our
first retail dispensary in Virginia, two additional stores in
Illinois, and further enhancing our newly acquired grower-processor
facility in Scranton, Pennsylvania.”
Mr. Cacioppo added, “We continued to see strong
momentum in the business as we exited the third quarter, and as a
result, we expect to see further expansion in revenue and
profitability through the balance of the year. We continue to
optimize our operations, including allowing more transactions to be
fulfilled through our online reservation system at
BEYOND-HELLO.com, adding additional point-of-sale stations in our
stores in Illinois and Pennsylvania, and leveraging data analytics
to offer more targeted promotions. We have also upgraded our talent
by adding several new hires in the third quarter with expertise in
retail, cultivation, and security. The positive impact of these
changes is just beginning to be realized, and we expect to be able
to continue to deliver strong results in the fourth quarter and
full-year 2021.”
Financial Results for the
Third Quarter
Ended September
30,
2020
($ in thousands, except per share amounts)
|
Quarter EndedSeptember 30, 2020 |
Quarter EndedJune 30, 2020 |
% change |
Revenue |
$ |
24,913 |
|
$ |
14,932 |
|
67 |
% |
Gross
profit |
$ |
12,250 |
|
$ |
7,472 |
|
64 |
% |
Net (loss)
income |
$ |
(29,999 |
) |
$ |
(9,308 |
) |
|
Net (loss)
income per share – basic |
$ |
(0.31 |
) |
$ |
(0.10 |
) |
|
Net (loss)
income per share - diluted |
$ |
(0.31 |
) |
$ |
(0.10 |
) |
|
Adjusted
EBITDA (loss) 1 |
$ |
1,930 |
|
$ |
(1,213 |
) |
|
|
|
|
|
Revenue in the third quarter of 2020 ("Q3 2020") increased 67
percent to $24.9 million, compared to $14.9 million in the second
quarter of 2020 (“Q2 2020”). The 67 percent increase in revenue was
primarily driven by strong revenue growth at the Company’s
BEYOND/HELLOTM stores in Illinois and Pennsylvania, a partial
contribution from the recently acquired Pennsylvania
grower-processor permit holder, and improved market conditions in
Nevada. On a same-store sales basis, revenue increased by
approximately 45%, compared to the second quarter of 2020,
excluding two temporarily closed stores in Philadelphia.
Gross profit in Q3 2020 was $12.3 million,
resulting in a gross margin of 49 percent, compared to $7.5 million
with a gross margin of 50 percent in Q2 2020. The $4.8 million, or
64 percent increase in gross profit over the prior quarter was
primarily due to an increase in retail sales, the addition of the
Pennsylvania grower-processor, improved product mix, improved
procurement of product and more disciplined promotional offers.
Q3 2020 net loss was $30 million, or $0.31 per
diluted share, compared to a net loss of $9.3 million, or $0.10 per
diluted share, in Q2 2020. The $20.7 million increase in net loss
in the third quarter was driven primarily by the increase in the
derivative warrant liability prompted by the rise of the Company’s
share price from $1.31 at June 30, 2020 to $2.44 at September 30,
2020, partially offset by a net gain on a business combination,
higher revenue and gross profit.
Adjusted EBITDA1 in Q3 2020 was $1.9 million,
compared to Adjusted EBITDA (Loss) $(1.2) million in Q2 2020.
Balance Sheet and Liquidity
As of September 30, 2020, the Company had $35.8
million of cash, as well as $7.4 million in short-term investments.
Total current assets of $62.6 million and current liabilities of
$41.2 million as of September 30, 2020. Net working capital at the
end of September 30, 2020 was $21.4 million. The Company
expects to
incur capital expenditures of approximately $7
million to $8 million during the fourth quarter of
2020 and $25 million to $30 million during
2021, subject to market conditions. As of September 30, 2020,
the Company had $99.0 million principal amount of total debt,
excluding leases and property, plant and equipment financing
obligations.
Subsequent to the quarter ended September 30,
2020, the Company received approximately $29 million in net
proceeds for its overnight marketed equity financing round. As of
October 31, 2020, the Company had approximately $73 million in cash
and short-term investments, is fully funded for the build-out of
the current portfolio, and has excess liquidity to pursue
opportunistic acquisitions.
Operations Update
Pennsylvania:In August 2020,
Jushi announced the closing of its equity acquisition of a
Pennsylvania Grower-Processor permit holder. The acquisition adds a
90,000 sq. ft. cannabis cultivation and processing facility that is
strategically located within minutes of Interstate 81, Interstate
84 and the Pennsylvania Turnpike, enabling efficient wholesale
distribution to the 98 dispensaries currently open across the
Commonwealth, including the Company’s eight operational
BEYOND/HELLOTM dispensaries in Pennsylvania.
Since closing the acquisition, the Company’s focus has shifted
to optimizing the facility to ensure long term growth and market
share expansion in the Pennsylvania market. Jushi has begun
implementing a series of operational and facility improvements,
including introducing new extraction technologies and equipment,
implementing complete facility automation, and improving room
utilization to double overall yield while increasing product
quality. These upgrades, which will be implemented over the next
twelve months, are expected to significantly increase the
production of both pre-packaged flower and extracted products.
Furthermore, as mentioned above, Jushi plans to significantly
expand the building footprint as well as the cultivation space.
On July 15, 2020, in partnership with Agape
Total Healthcare Inc, Jushi opened one new dispensary in Reading,
Pennsylvania, bringing its total store count in the Commonwealth to
eight medical dispensaries operating under the BEYOND/HELLOTM
brand. The Company anticipates further consolidating its retail
footprint in Pennsylvania, and opening an additional seven
locations by the end of the third quarter 2021.
Illinois: Jushi operates two
BEYOND/HELLOTM retail stores in Illinois, serving both medical and
adult-use customers. The stores are located in Sauget (adjacent to
East St. Louis) and Normal (Bloomington-Normal metro area). Each
store is also eligible to seek approval from the Illinois
Department of Financial & Professional Regulation to open a
second adult-use retail location, and such second retail locations
are currently undergoing regulatory approvals and are under
construction. Jushi plans to exercise both options and open the
second Sauget location in December 2020 and the second
Bloomington-Normal location in January 2021.
Virginia: In August 2020,
Jushi’s majority owned Dalitso LLC, a Virginia-based pharmaceutical
processor for medical cannabis extracts, received approval from the
Virginia Board of Pharmacy to commence vertically integrated
operations for the cultivation, processing, dispensing, and
delivery of medical cannabis products to registered patients in
Virginia. Dalitso is one of only five applications to have received
conditional approval for a pharmaceutical processor permit issued
by the Virginia Board of Pharmacy and one of only four to have
received final approval and permit issuance.
In November 2020, the Company announced it
commenced operations at Dalitso’s pharmaceutical processor facility
near the City of Manassas, and will be officially opening its first
BEYOND/HELLOTM medical dispensary in Virginia on December 1,
2020. The Company also anticipates adding an
additional five BEYOND/HELLOTM branded medical dispensaries in
Virginia. The Company is targeting opening stores in Fairfax,
Leesburg, Falls Church, Woodbridge, Arlington and Tysons
Corner.
California: In October 2020,
Jushi opened its 11th retail location nationally:
BEYOND/HELLOTM Santa Barbara and its first store in California. The
city of Santa Barbara is a limited license market and currently
only allows for three dispensaries to operate in the jurisdiction.
The Company also previously signed a $3.1 million financing
arrangement related to the real estate previously purchased in
connection with this license. As previously disclosed, the Company
plans to continue to develop its plans related to moving forward in
the merit-based application process as one of only three selected
applicants for a storefront retail (and ancillary delivery) permit
in Culver City, California.
The Company will continue to pursue additional retail
opportunities in specific limited license markets in California,
particularly jurisdictions with high barriers of entry, limited
market participants, and a firm handle on the local unregulated
market.
Outlook
Mr. Cacioppo commented, “As a result of our
expectation for continued strong operating results for the
remainder of the year, we are increasing our fourth quarter 2020
revenues guidance from $25 to $30 million to $28 to $30 million and
expect fourth quarter 2020 Adjusted EBITDA to be between $2.5 and
$3.0 million. For the first quarter of 2021, we expect revenues to
be between $37 and $40 million and Adjusted EBITDA to be between
$4.0 to $5.0 million. We are also maintaining our 2021 revenue
guidance of $205 to $255 million and our 2021 Adjusted EBITDA
guidance of approximately $40 to $50 million.”
Mr. Cacioppo added, “Jushi’s growing retail
footprint and best-in-class cultivation and processing assets are
supported by strong managerial, operational experience, deep
consumer insights, award-winning genetics, and a comprehensive
suite of innovative brands. Through strategic M&A and key
management hires, we have built a strong foundation to continue to
drive outsized performance as we execute on the opportunity
ahead.”
The Company’s MD&A and consolidated
financial statements for the third quarter September 30, 2020,
along with all previous public filings of the Company, may be found
on SEDAR at www.SEDAR.com.
Conference Call and Webcast
InformationManagement will host a conference call and
audio webcast on Tuesday, November 24th at 9:00 a.m. ET to answer
questions about the Company's operational and financial highlights.
The dial-in numbers for the conference call are +1-877-407-0792
(U.S. Toll-Free) or +1-201-689-8263 (International). Please dial in
10 to 15 minutes prior to the start time of the conference call and
an operator will register your name and organization.
The conference call will also be available via
webcast, which can be accessed through the Investor Relations
section of Jushi's website, http://ir.jushico.com/.
For interested individuals unable to join the
conference call, an audio webcast replay will be available and can
be accessed on Jushi’s Investor Relations site,
http://ir.jushico.com/.
About Jushi Holdings Inc. We
are a vertically integrated cannabis company led by an industry
leading management team. In the United States Jushi is focused on
building a multi-state portfolio of branded cannabis assets through
opportunistic acquisitions, distressed workouts, and competitive
applications. Jushi strives to maximize shareholder value while
delivering high quality products across all levels of the cannabis
ecosystem. For more information please
visit www.jushico.com or our social media
channels, Instagram, Facebook, Twitter, and LinkedIn.
Forward-Looking Information and
Statements
This press release contains certain
"forward-looking information" within the meaning of applicable
Canadian securities legislation and may also contain statements
that may constitute "forward-looking statements" within the meaning
of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such forward-looking
information and forward-looking statements are not representative
of historical facts or information or current conditions but
instead represent only the Company’s beliefs regarding future
events, plans or objectives, many of which, by their nature, are
inherently uncertain and outside of the Company’s control.
Generally, such forward-looking information or forward-looking
statements can be identified by the use of forward-looking
terminology such as “plans,” “expects” or “does not expect,” “is
expected,” “budget,” “scheduled,” “estimates,” “forecasts,”
“intends,” “anticipates” or “does not anticipate,” or “believes,”
or variations of such words and phrases or may contain statements
that certain actions, events or results “may,” “could,” “would,”
“might” or “will be taken,” “will continue,” “will occur” or “will
be achieved”. The forward-looking information and forward-looking
statements contained herein may include but are not limited to,
information concerning the expectations regarding Jushi, or the
ability of Jushi to successfully achieve business objectives, and
expectations for other economic, business, and/or competitive
factors.
By identifying such information and statements
in this manner, the Company is alerting the reader that such
information and statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
information and statements. In addition, in connection with the
forward-looking information and forward-looking statements
contained in this press release, the Company has made certain
assumptions. Among the key factors that could cause actual results
to differ materially from those projected in the forward-looking
information and statements are the following: the ability of Jushi
to successfully achieve business objectives, including with
regulatory bodies, employees, suppliers, customers and competitors;
changes in general economic, business and political conditions,
including changes in the financial markets; changes in applicable
laws; and compliance with extensive government regulation, as well
as other risks and uncertainties which are more fully described in
the Company’s Management, Discussion and Analysis for the three
months ended September 30, 2020, and other filings with securities
and regulatory authorities which are available at www.sedar.com.
Should one or more of these risks, uncertainties or other factors
materialize, or should assumptions underlying the forward-looking
information or statements prove incorrect, actual results may vary
materially from those described herein as intended, planned,
anticipated, believed, estimated or expected.
Although the Company believes that the
assumptions and factors used in preparing, and the expectations
contained in, the forward-looking information and statements are
reasonable, undue reliance should not be placed on such information
and statements, and no assurance or guarantee can be given that
such forward-looking information and statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such information and
statements. The forward-looking information and forward-looking
statements contained in this press release are made as of the date
of this press release, and the Company does not undertake to update
any forward-looking information and/or forward-looking statements
that are contained or referenced herein, except in accordance with
applicable securities laws. All subsequent written and oral
forward-looking information and statements attributable to the
Company or persons acting on its behalf is expressly qualified in
its entirety by this notice.
Not for distribution to United States newswire services
or for dissemination in the United States.
For further information, please
contact:
Investor RelationsMichael PerlmanExecutive Vice
President of Investor Relations and
TreasuryInvestors@jushico.com(561) 453-1308
Media ContactEllen MellodyMATTIO
CommunicationsEllen@Mattio.com (570) 209-2947
JUSHI
HOLDINGS INC. AND SUBSIDIARIES |
CONDENSED
UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS) |
(in thousands of
U.S. dollars, except share and per share amounts) |
|
|
|
|
|
Three Months EndedSeptember 30, 2020 |
|
Three Months EndedJune 30, 2020 |
|
Three Months EndedSeptember 30, 2019 |
|
(unaudited) |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue,
net |
$ |
24,913 |
|
|
$ |
14,932 |
|
|
$ |
3,588 |
|
Cost of
goods sold |
|
(13,888 |
) |
|
|
(7,495 |
) |
|
|
2,066 |
|
Gross profit
before fair value changes |
$ |
11,025 |
|
|
$ |
7,437 |
|
|
$ |
1,522 |
|
Realized fair value changes included in inventory sold |
|
(761 |
) |
|
|
(33 |
) |
|
|
- |
|
Unrealized fair value changes included in biological assets |
|
1,986 |
|
|
|
68 |
|
|
|
26 |
|
Gross
profit |
$ |
12,250 |
|
|
$ |
7,472 |
|
|
$ |
1,548 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses |
$ |
4,295 |
|
|
$ |
3,757 |
|
|
$ |
3,608 |
|
Salaries, wages and employee related expenses |
|
4,964 |
|
|
|
4,994 |
|
|
|
4,040 |
|
Share-based compensation expense |
|
1,274 |
|
|
|
1,211 |
|
|
|
1,821 |
|
Acquisition and deal costs |
|
88 |
|
|
|
159 |
|
|
|
30 |
|
Depreciation and amortization expense |
|
1,310 |
|
|
|
1,064 |
|
|
|
787 |
|
Total
operating expenses |
$ |
11,931 |
|
|
$ |
11,185 |
|
|
$ |
10,286 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
(loss) from operations before other (expense) income |
$ |
319 |
|
|
$ |
(3,713 |
) |
|
$ |
(8,738 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Other
(expense) income: |
|
|
|
|
|
|
|
|
|
|
|
Interest income |
$ |
69 |
|
|
$ |
38 |
|
|
$ |
114 |
|
Fair value changes in derivative warrants |
|
(36,888 |
) |
|
|
(3,748 |
) |
|
|
- |
|
Interest expense and finance charges |
|
(6,791 |
) |
|
|
(3,435 |
) |
|
|
(1,039 |
) |
Net gains on business combination |
|
15,313 |
|
|
|
- |
|
|
|
- |
|
Gains (losses) on investments and financial assets |
|
1,654 |
|
|
|
2,332 |
|
|
|
9,222 |
|
Listing expense |
|
- |
|
|
|
- |
|
|
|
- |
|
Other (expense) income |
|
(1,826 |
) |
|
|
235 |
|
|
|
4,986 |
|
Total other
(expense) income, net |
$ |
(28,469 |
) |
|
$ |
(4,578 |
) |
|
$ |
13,283 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss)
income and comprehensive (loss) income before tax |
$ |
(28,150 |
) |
|
$ |
(8,291 |
) |
|
$ |
4,545 |
|
Income tax expense |
|
(1,849 |
) |
|
|
(1,017 |
) |
|
|
(389 |
) |
Net (loss)
income and comprehensive (loss) income |
$ |
(29,999 |
) |
|
$ |
(9,308 |
) |
|
$ |
4,156 |
|
Net loss attributable to non-controlling interests |
|
(573 |
) |
|
|
(429 |
) |
|
|
(71 |
) |
Net (loss)
income and comprehensive (loss) income attributable to Jushi
shareholders |
$ |
(29,426 |
) |
|
$ |
(8,879 |
) |
|
$ |
4,227 |
|
Net (loss)
income and comprehensive (loss) income per share attributable to
Jushi shareholders - basic |
$ |
(0.31 |
) |
|
$ |
(0.10 |
) |
|
$ |
0.05 |
|
Weighted
average shares outstanding - basic |
|
93,572,969 |
|
|
|
92,264,221 |
|
|
|
93,238,354 |
|
Net (loss)
income and comprehensive (loss) income per share attributable to
Jushi shareholders - diluted |
$ |
(0.31 |
) |
|
$ |
(0.10 |
) |
|
$ |
0.04 |
|
Weighted
average shares outstanding - diluted |
|
93,572,969 |
|
|
|
92,264,221 |
|
|
|
110,039,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
JUSHI
HOLDINGS INC. AND SUBSIDIARIES |
CONDENSED
UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF |
FINANCIAL POSITION |
(in thousands of
U.S. dollars) |
|
|
|
|
|
September 30, 2020 |
|
December 31, 2019 |
|
|
|
|
ASSETS |
|
|
|
CURRENT
ASSETS: |
|
|
|
Cash |
$ |
35,767 |
|
|
$ |
38,936 |
|
Investments in securities |
|
7,431 |
|
|
|
12,267 |
|
Other short-term financial assets |
|
- |
|
|
|
5,646 |
|
Accounts receivable |
|
1,052 |
|
|
|
395 |
|
Prepaid expenses |
|
4,552 |
|
|
|
2,565 |
|
Inventory |
|
7,092 |
|
|
|
1,958 |
|
Biological assets |
|
3,640 |
|
|
|
271 |
|
Deferred acquisition costs |
|
- |
|
|
|
2,320 |
|
Other current assets |
|
3,046 |
|
|
|
188 |
|
Total current assets |
$ |
62,580 |
|
|
$ |
64,546 |
|
|
|
|
|
NON-CURRENT
ASSETS: |
|
|
|
Purchase option |
|
2,670 |
|
|
|
- |
|
Property, plant and equipment |
|
68,015 |
|
|
|
22,592 |
|
Other long-term assets |
|
1,580 |
|
|
|
1,181 |
|
Other intangible assets, net |
|
140,327 |
|
|
|
93,686 |
|
Goodwill |
|
28,055 |
|
|
|
28,055 |
|
Total long-term assets |
$ |
240,647 |
|
|
$ |
145,514 |
|
Total
assets |
$ |
303,227 |
|
|
$ |
210,060 |
|
|
|
|
|
LIABILITIES
AND EQUITY |
|
|
|
CURRENT
LIABILITIES: |
|
|
|
Accounts payable |
$ |
3,618 |
|
|
$ |
1,182 |
|
Accrued expenses and other current liabilities |
|
21,678 |
|
|
|
7,691 |
|
Short-term promissory notes payable |
|
11,876 |
|
|
|
15,635 |
|
Short-term lease obligations |
|
4,034 |
|
|
|
969 |
|
Short-term redemption liability |
|
- |
|
|
|
8,440 |
|
Total current liabilities |
$ |
41,206 |
|
|
$ |
33,917 |
|
|
|
|
|
LONG-TERM
LIABILITIES: |
|
|
|
Other liabilities |
$ |
2,842 |
|
|
$ |
2 |
|
Long-term promissory notes payable |
|
2,696 |
|
|
|
9,988 |
|
Senior notes |
|
46,514 |
|
|
|
10,736 |
|
Derivative warrants liability |
|
77,919 |
|
|
|
5,529 |
|
Long-term lease obligations |
|
34,705 |
|
|
|
5,529 |
|
Deferred tax liabilities |
|
25,709 |
|
|
|
20,334 |
|
Total
liabilities |
$ |
231,591 |
|
|
$ |
86,035 |
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES |
|
|
|
|
|
|
|
EQUITY: |
|
|
|
Share capital and share reserves |
$ |
162,292 |
|
|
$ |
163,032 |
|
Accumulated deficit |
|
(102,588 |
) |
|
|
(48,667 |
) |
Total Jushi shareholders' equity |
$ |
59,704 |
|
|
$ |
114,365 |
|
Non-controlling interests |
|
11,932 |
|
|
|
9,660 |
|
Total equity |
$ |
71,636 |
|
|
$ |
124,025 |
|
Total
liabilities and equity |
$ |
303,227 |
|
|
$ |
210,060 |
|
|
|
|
|
|
|
|
|
JUSHI HOLDINGS INC. AND SUBSIDIARIES |
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH
FLOWS |
(in thousands of U.S. dollars) |
|
|
|
|
|
Nine Months EndedSeptember 30, 2020 |
|
Nine Months EndedSeptember 30, 2019 |
|
|
|
|
CASH FLOWS FROM OPERATING
ACTIVITIES: |
|
|
|
Net loss |
$ |
(55,203 |
) |
|
$ |
(13,642 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
- |
|
|
|
- |
|
Depreciation and amortization, include amounts in costs of goods
sold |
|
3,508 |
|
|
|
1,200 |
|
Share-based payments |
|
3,804 |
|
|
|
3,752 |
|
Fair value changes in derivative warrants |
|
38,049 |
|
|
|
- |
|
Net gain on business combination |
|
(17,515 |
) |
|
|
- |
|
Losses (gains) on investments and financial assets |
|
4,225 |
|
|
|
(9,252 |
) |
Finance charge on lease liabilities and financing obligations |
|
2,006 |
|
|
|
299 |
|
Other non-cash interest expense |
|
5,278 |
|
|
|
318 |
|
Deferred income taxes |
|
(4,331 |
) |
|
|
- |
|
Fair value changes on sale of inventory and on biological
assets |
|
(1,333 |
) |
|
|
(26 |
) |
Non-cash listing expense |
|
- |
|
|
|
1,361 |
|
Non-cash other expense, net |
|
2,634 |
|
|
|
172 |
|
Changes in operating assets and liabilities, net of
acquisitions: |
|
|
|
Accounts receivable |
$ |
(251 |
) |
|
$ |
128 |
|
Prepaid expenses and other current assets |
|
(4,014 |
) |
|
|
(6,920 |
) |
Inventory and biological assets |
|
(1,236 |
) |
|
|
(1,759 |
) |
Other long-term assets |
|
(165 |
) |
|
|
(646 |
) |
Accounts payable, accrued expenses and other current
liabilities |
|
12,051 |
|
|
|
3,294 |
|
Other long-term liabilities |
|
|
|
(380 |
) |
Net cash flows used in operating activities |
$ |
(12,493 |
) |
|
$ |
(22,101 |
) |
|
|
|
|
CASH FLOWS FROM INVESTING
ACTIVITIES: |
|
|
|
Payments for acquisitions, net of cash acquired |
$ |
(27,458 |
) |
|
$ |
(46,967 |
) |
Payments for deferred acquisition costs |
|
- |
|
|
|
(4,270 |
) |
Purchases of property, plant and equipment |
|
(12,417 |
) |
|
|
(6,949 |
) |
Sales and redemptions of investments in securities |
|
12,157 |
|
|
|
- |
|
Payments for investments in securities |
|
(10,000 |
) |
|
|
- |
|
Proceeds from (investment in) financial asset |
|
5,193 |
|
|
|
(100 |
) |
Net cash flows used in investing activities |
$ |
(32,525 |
) |
|
$ |
(58,286 |
) |
|
|
|
|
CASH FLOWS FROM FINANCING
ACTIVITIES: |
|
|
|
Issuance of shares for cash, net |
|
- |
|
|
$ |
79,519 |
|
Proceeds from exercise of warrants |
|
596 |
|
|
|
569 |
|
Proceeds from issuance of 10% Senior Notes and derivative warrants,
net of financing costs |
|
51,868 |
|
|
|
- |
|
Principal and financing costs on promissory notes payable |
|
(13,726 |
) |
|
|
(10,602 |
) |
Payments on lease obligations |
|
(1,876 |
) |
|
|
(433 |
) |
Proceeds from financing obligation, net of payments |
|
3,017 |
|
|
|
- |
|
Contribution from non-controlling interests, net |
|
1,994 |
|
|
|
- |
|
Net cash flows provided by financing activities |
$ |
41,873 |
|
|
$ |
69,053 |
|
|
|
|
|
Effect of currency translation
on cash |
|
(24 |
) |
|
|
- |
|
|
|
|
|
NET CHANGE IN CASH |
$ |
(3,169 |
) |
|
$ |
(11,334 |
) |
|
|
|
|
CASH, BEGINNING OF PERIOD |
|
38,936 |
|
|
|
38,114 |
|
|
|
|
|
CASH, END OF PERIOD |
$ |
35,767 |
|
|
$ |
26,780 |
|
JUSHI HOLDINGS
INC.RECONCILIATION OF NON-IFRS FINANCIAL
MEASURES
EBITDA and Adjusted
EBITDA are financial measures that are not
defined under IFRS. We define EBITDA as net income (loss), or
“earnings”, before interest, income taxes, depreciation, and
amortization. We define Adjusted EBITDA as EBITDA before: (i) fair
value changes on biological assets and fair value changes on sale
of inventory; (ii) share-based compensation expense; (iii) fair
value changes in derivative warrants; (iv) net gain on business
combination; (v) gains and losses on investments and financial
assets; and (vi) gains and losses on legal settlements.
Adjusted EBITDA is not a recognized performance
measure under IFRS, does not have a standardized meaning and
therefore may not be comparable to similar measures presented by
other issuers. Adjusted EBITDA is included as a supplemental
disclosure because we believe that such measurement provides a
better assessment of the Company's operations on a continuing basis
by eliminating certain material non-cash items and certain other
adjustments we believe are not reflective of the Company's ongoing
operations and performance. Adjusted EBITDA has limitations as an
analytical tool as it excludes from net income as reported
interest, tax, depreciation, non-cash expenses, RTO expense, other
income, grow cost expensed for biological assets and unsold
inventory, and the non-cash fair value effects of accounting for
biological assets and inventories. Because of these limitations,
Adjusted EBITDA should not be considered as the sole measure of the
Company's performance and should not be considered in isolation
from, or as a substitute for, analysis of the Company's results as
reported under IFRS. The most directly comparable measure to
Adjusted EBITDA calculated in accordance with IFRS is operating
income (loss).
Jushi includes a store in the same-store base if
the store is operational for two consecutive full quarters. A store
is not included in same-store sales if it is closed for one week or
longer, such as for business interruption, remodeling, during the
stated period. Same-store sales growth is primarily a result of
changes in the number of customer transactions and changes in the
average transaction size. Jushi’s same-store sales growth is
primarily impacted by the expansion of its brand awareness,
continued menu innovation and the use technology. Jushi’s
same-store sales growth is also impacted by external factors
including the macro-economic environment that could affect consumer
spending.
JUSHI
HOLDINGS INC. AND SUBSIDIARIES |
Unaudited
Reconciliation of Net Loss to Adjusted EBITDA |
(in thousands of
U.S. dollars) |
|
|
|
|
|
Three Months Ended September 30, 2020 |
|
Three Months Ended June 30, 2020 |
|
|
Net loss |
$ |
(29,999 |
) |
|
$ |
(9,308 |
) |
Income tax
expense |
|
1,849 |
|
|
|
1,017 |
|
Interest
expense, net |
|
6,722 |
|
|
|
3,397 |
|
Depreciation
and amortization (1) |
|
1,370 |
|
|
|
1,089 |
|
EBITDA (Non-IFRS) |
$ |
(20,058 |
) |
|
$ |
(3,805 |
) |
Non-cash
share-based compensation |
|
1,274 |
|
|
|
1,211 |
|
Fair value
changes on sale of inventory and on biological assets |
|
(1,225 |
) |
|
|
(35 |
) |
Fair value
changes in derivative warrants |
|
36,888 |
|
|
|
3,748 |
|
Net gain on
business combinations |
|
(15,313 |
) |
|
|
- |
|
(Gains) on
investments and financial assets |
|
(1,654 |
) |
|
|
(2,332 |
) |
Loss on
legal settlement |
|
2,018 |
|
|
|
- |
|
Adjusted EBITDA (Non-IFRS) |
$ |
1,930 |
|
|
$ |
(1,213 |
) |
|
|
|
|
(1) Includes
depreciation included in cost of goods sold |
|
|
|
Jushi (CSE:JUSH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Jushi (CSE:JUSH)
Historical Stock Chart
From Dec 2023 to Dec 2024